Myocardial recovery is common when left ventricular assist devices (LVADs) are combined with aggressive pharmacological management, according to results from an US observational study.

In RESTAGE-HF, a prospective, six-centre, non-randomised study, US researchers investigated whether a uniform protocol of LVAD pump-speed optimisation combined with an aggressive drug regimen and regular testing of underlying myocardial function could lead to an enhanced rate of myocardial recovery.